Dr. Brentjens on Research Beyond CD19 in CAR T-Cell Therapy
Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for CAR T-cell therapy.
Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy.
CD19 is a well-established target in B-cell cancer, with 2 commercially available CAR T-cell therapies targeting tumor cells that express CD19.
Brentjens says that CD19 is only the beginning, as other targets are emerging such as BCMA. Clinical trials targeting BCMA in patients with relapsed or refractory multiple myeloma are currently ongoing.
Recent Videos
